Compare KFY & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFY | IRON |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.4B |
| IPO Year | 1999 | N/A |
| Metric | KFY | IRON |
|---|---|---|
| Price | $66.52 | $79.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $78.00 | ★ $108.85 |
| AVG Volume (30 Days) | 579.0K | ★ 753.6K |
| Earning Date | 12-09-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | ★ 5.12 | N/A |
| EPS | ★ 4.91 | N/A |
| Revenue | ★ $2,811,089,000.00 | N/A |
| Revenue This Year | $4.54 | N/A |
| Revenue Next Year | $4.41 | N/A |
| P/E Ratio | $13.70 | ★ N/A |
| Revenue Growth | ★ 3.78 | N/A |
| 52 Week Low | $59.23 | $30.82 |
| 52 Week High | $78.50 | $99.50 |
| Indicator | KFY | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 45.74 | 33.29 |
| Support Level | $68.28 | $71.41 |
| Resistance Level | $69.77 | $92.00 |
| Average True Range (ATR) | 1.50 | 4.73 |
| MACD | -0.00 | -1.91 |
| Stochastic Oscillator | 24.89 | 29.60 |
Korn Ferry is a consulting firm that powers performance. The Company helps unlock the potential in people and unleash transformation across organizations synchronizing, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. The company's segment includes Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search APAC, Executive Search Latin America, Professional Search & Interim and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.